Kazia Therapeutics Limited (KZIA): Price and Financial Metrics

Kazia Therapeutics Limited (KZIA): $11.45

0.31 (+2.78%)

POWR Rating

Component Grades













Add KZIA to Watchlist
Sign Up

Industry: Biotech


of 498

in industry


  • Sentiment is the dimension where KZIA ranks best; there it ranks ahead of 82.05% of US stocks.
  • The strongest trend for KZIA is in Growth, which has been heading up over the past 31 weeks.
  • KZIA's current lowest rank is in the Quality metric (where it is better than 6.05% of US stocks).

KZIA Stock Summary

  • With a one year PEG ratio of 2,954.66, Kazia Therapeutics Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.8% of US stocks.
  • The ratio of debt to operating expenses for Kazia Therapeutics Ltd is higher than it is for about merely 0.49% of US stocks.
  • Revenue growth over the past 12 months for Kazia Therapeutics Ltd comes in at -75.47%, a number that bests only 2.33% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Kazia Therapeutics Ltd, a group of peers worth examining would be VNE, SLGL, SNGX, LEGN, and LIFE.
  • KZIA's SEC filings can be seen here. And to visit Kazia Therapeutics Ltd's official web site, go to www.kaziatherapeutics.com.

KZIA Stock Price Chart Interactive Chart >

Price chart for KZIA

KZIA Price/Volume Stats

Current price $11.45 52-week high $15.85
Prev. close $11.14 52-week low $5.55
Day low $11.05 Volume 22,500
Day high $11.50 Avg. volume 87,657
50-day MA $9.71 Dividend yield N/A
200-day MA $10.15 Market Cap 148.41M

Kazia Therapeutics Limited (KZIA) Company Bio

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

KZIA Latest News Stream

Event/Time News Detail
Loading, please wait...

KZIA Latest Social Stream

Loading social stream, please wait...

View Full KZIA Social Stream

Latest KZIA News From Around the Web

Below are the latest news stories about Kazia Therapeutics Ltd that investors may wish to consider to help them evaluate KZIA as an investment opportunity.

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021.

Yahoo | September 10, 2021

Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Yahoo | September 7, 2021

When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven?

With the business potentially at an important milestone, we thought we'd take a closer look at Kazia Therapeutics...

Yahoo | August 2, 2021

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government

PR Newswire | July 21, 2021

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.

Yahoo | June 30, 2021

Read More 'KZIA' Stories Here

KZIA Price Returns

1-mo 21.16%
3-mo 14.84%
6-mo N/A
1-year 70.90%
3-year 256.70%
5-year 41.01%
YTD 32.52%
2020 99.08%
2019 78.60%
2018 -23.58%
2017 -45.92%
2016 -29.67%

Continue Researching KZIA

Want to see what other sources are saying about Kazia Therapeutics Ltd's financials and stock price? Try the links below:

Kazia Therapeutics Ltd (KZIA) Stock Price | Nasdaq
Kazia Therapeutics Ltd (KZIA) Stock Quote, History and News - Yahoo Finance
Kazia Therapeutics Ltd (KZIA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9596 seconds.